CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 8, 2019-- Synlogic, Inc. (NASDAQ: SYBX) announced today that Scott Plevy , M.D., Synlogic’s chief scientific officer, will provide a corporate update at the 2019 Wedbush PacGrow Healthcare Conference on Tuesday, August 13 at 9:45 am ET , in New York City ....

– Strong balance sheet supports clinical advancement of lead and emerging Synthetic Biotic ™ programs – –Bridging study to evaluate solid oral formulation of SYNB1618 open and recruiting healthy volunteers – – Company will host a conference call and webcast at 5:00 pm ET today – CAMBRIDGE, Mass....

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 1, 2019-- Synlogic, Inc. ( Nasdaq: SYBX ), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, announced today that the Company will release its second quarter 2019 financial results after the market...

– Data demonstrate statistically significant biomarker activity at well-tolerated dose in PKU patients – – Plan to initiate bridging study with new oral solid formulation in Q3 2019 – – Conference call and webcast today, July 15 , at 8:00 a.m. ET – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul....

– Fuels development of Synlogic’s growing pipeline of novel living medicines with technology access and $80.0 million equity investment at a premium – – Applies Ginkgo’s high-throughput synthetic biology platform services to human therapeutics – – Synlogic to host a conference call at 8:00 am ET...

CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 22, 2019-- Synlogic, Inc. , (Nasdaq: SYBX) a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced a new clinical collaboration with Roche (SIX:RO, ROG), to explore Synlogic’s Synthetic...

– Company will host a conference call and webcast at 5:00 pm ET today – CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 9, 2019-- Synlogic, Inc. ( Nasdaq: SYBX ), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today reported its financial...

CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 2, 2019-- Synlogic, Inc. ( Nasdaq: SYBX ), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, announced today that the Company will release its first quarter 2019 financial results after the market...

- Synlogic’s robust and reproducible lyophilization process provides a solid formulation of SYNB1618 with improved quality attributes, stability and minimal loss of viability compared to liquid formulation - CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 30, 2019-- Synlogic, Inc....

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 15, 2019-- Synlogic, Inc. , (Nasdaq: SYBX) a clinical-stage drug discovery and development company applying synthetic biology to probiotics to develop novel living medicines, today announced that data from its program to develop solid oral formulations of...

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 9, 2019-- Synlogic, Inc . (Nasdaq: SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced the appointment of Scott Plevy , M.D., as Chief Scientific Officer. Dr....

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 2, 2019-- Synlogic (Nasdaq:SYBX) announced today that Aoife Brennan , M.B., B.Ch., Synlogic’s president and chief executive officer, will provide a corporate update at the 18th Annual Needham Healthcare Conference at 3:30 pm ET on Tuesday, April 9, 2019 , in...